Scrip Asks… What Are The Biggest Barriers To Women In Leadership Roles?
Executive Summary
Scrip talked to five female CEOs about the barriers in biopharma that prevent more women from reaching the top leadership ranks and their thoughts on what industry can do to improve gender diversity.
You may also be interested in...
Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
High Deal Valuations & Volumes Will Persist, Industry Dealmakers Predict
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Latecomer Libtayo Wins Coveted First-Line NSCLC Monotherapy Indication
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports